228 related articles for article (PubMed ID: 17153267)
1. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
3. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A
Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
[TBL] [Abstract][Full Text] [Related]
4. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
8. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'Arco A; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S; Baccarani M; Cavo M
Blood; 2006 Dec; 108(12):3951-2. PubMed ID: 17114572
[No Abstract] [Full Text] [Related]
13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
16. [Avascular osteonecrosis of the jaws induced by diphosphonates].
Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
[No Abstract] [Full Text] [Related]
17. [Osteonecrosis associated with the use of biphosphonates: Case report].
Anguita C T; Agurto P J; Roa E I; Laissle C G
Rev Med Chil; 2006 Sep; 134(9):1161-5. PubMed ID: 17171218
[TBL] [Abstract][Full Text] [Related]
18. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J
Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
[TBL] [Abstract][Full Text] [Related]
19. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]